2025
Long term feeding tube use in head and neck cancer survivors – a secondary analysis of patient and treatment related factors
Galloway T, Pugh S, Ridge J, Nguyen-Tan P, Rosenthal D, Gillison M, Garden A, Dunlap N, Caudell J, Jones C, Bauman J, Bahig H, Shenouda G, Currey A, Koyfman S, Stokes W, Read N, Lyness J, Yom S, Le Q. Long term feeding tube use in head and neck cancer survivors – a secondary analysis of patient and treatment related factors. International Journal Of Radiation Oncology • Biology • Physics 2025 PMID: 40473230, DOI: 10.1016/j.ijrobp.2025.05.064.Peer-Reviewed Original ResearchIntensity modulated radiation therapyOropharynx cancer patientsOropharynx cancerFeeding tube useTube useAccelerated fractionationTreatment initiationPredictive factorsFeeding tubeIntensity modulated radiation therapy techniquesTreated with 3DCRTSecondary analysis of patientsT4 tumor stageAnalysis of patientsTreatment related factorsPost hoc secondary analysisTreatment completionYears of smokingSecondary analysisChemoradiation trialsConcurrent chemotherapyMedian followupConcomitant boostConformal radiationRadiation therapy
2021
Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series
Kowalczyk K, Madi R, Eden C, Sooriakumaran P, Fransis K, Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi A, Hwang J, Kim I, Hu J. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. Journal Of Urology 2021, 206: 1184-1191. PMID: 34181471, DOI: 10.1097/ju.0000000000001939.Peer-Reviewed Original ResearchConceptsRobotic-assisted radical prostatectomyAssisted radical prostatectomyConsole timeRadical prostatectomyPrimary treatmentStereotactic body radiation therapyFeasible salvage optionNonsurgical primary treatmentPostoperative pad useUrinary function outcomesRisk of incontinenceKaplan-Meier curvesBody radiation therapyProportional hazards modelLonger console timeT-testStudent's t-testPostoperative complicationsMedian followupOncologic outcomesPerioperative dataBlood lossComplication rateSalvage optionFunction outcomes
2015
Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease
Tsao C, Gray K, Nakabayashi M, Evan C, Kantoff P, Huang J, Galsky M, Pomerantz M, Oh W. Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. Journal Of Urology 2015, 194: 91-97. PMID: 25623747, DOI: 10.1016/j.juro.2015.01.078.Peer-Reviewed Original ResearchConceptsDefinitive local therapyGleason 8 diseaseGleason score 8Gleason 9Increased risk of deathRadiation therapyLocal therapyRisk of deathIncreased riskGleason 8Radical prostatectomyScore 8Associated with higher prostate specific antigenPatients treated with radical prostatectomyBiopsy Gleason score 8Gleason 9-10 diseaseHigher prostate specific antigenNeoadjuvant/adjuvant androgen deprivation therapyAndrogen deprivation therapyHigh grade diseaseBaseline patient characteristicsProstate specific antigenMultivariate Cox modelMedian followupBiochemical recurrence
2014
Ultrasensitive Prostate Specific Antigen after Prostatectomy Reliably Identifies Patients Requiring Postoperative Radiotherapy
Kang JJ, Reiter RE, Steinberg ML, King CR. Ultrasensitive Prostate Specific Antigen after Prostatectomy Reliably Identifies Patients Requiring Postoperative Radiotherapy. Journal Of Urology 2014, 193: 1532-1538. PMID: 25463990, PMCID: PMC4527538, DOI: 10.1016/j.juro.2014.11.017.Peer-Reviewed Original ResearchConceptsUltrasensitive prostate specific antigenProstate-specific antigenInitial prostate-specific antigenPostoperative prostate-specific antigenBiochemical relapseSpecific antigenHigh riskRadical prostatectomyPostoperative radiotherapyT stageGleason gradeMultivariate analysisProstate-specific antigen (PSA) recurrenceEventual biochemical failureSpecific antigen recurrenceCox multivariate analysisTraditional risk factorsConventional prostate specific antigenBiochemical failureIdentifies patientsMedian followupMargin statusPathology findingsKaplan-MeierPositive marginsBladder Volume at Onset of Vesicoureteral Reflux is an Independent Risk Factor for Breakthrough Febrile Urinary Tract Infection
Alexander S, Arlen A, Storm D, Kieran K, Cooper C. Bladder Volume at Onset of Vesicoureteral Reflux is an Independent Risk Factor for Breakthrough Febrile Urinary Tract Infection. Journal Of Urology 2014, 193: 1342-1346. PMID: 25305355, DOI: 10.1016/j.juro.2014.10.002.Peer-Reviewed Original ResearchConceptsBreakthrough febrile urinary tract infectionFebrile urinary tract infectionUrinary tract infectionOnset of refluxBladder-bowel dysfunctionRisk of pyelonephritisTract infectionsVesicoureteral refluxBladder volumeReflux gradeRecurrent febrile urinary tract infectionsMedian bladder volumeIndependent risk factorAdditional prognostic informationIdentification of childrenDuration of exposureReflux onsetBladder capacityMedian followupSD agePrognostic informationRisk factorsMultivariate analysisClinical decisionInfection
2013
Preoperative Pulmonary Embolism Does Not Predict Poor Postoperative Outcomes in Patients with Renal Cell Carcinoma and Venous Thrombus
Abel EJ, Wood CG, Eickstaedt N, Fang JE, Kenney P, Bagrodia A, Youssef RF, Sagalowsky AI, Margulis V. Preoperative Pulmonary Embolism Does Not Predict Poor Postoperative Outcomes in Patients with Renal Cell Carcinoma and Venous Thrombus. Journal Of Urology 2013, 190: 452-457. PMID: 23434945, DOI: 10.1016/j.juro.2013.02.033.Peer-Reviewed Original ResearchConceptsPreoperative pulmonary embolismCancer-specific survivalRenal cell carcinomaPulmonary embolismPoor postoperative outcomesCell carcinomaSpecific survivalVenous thrombiPostoperative outcomesMetastatic renal cell carcinomaCox proportional hazards analysisWorse cancer-specific survivalConsecutive patient recordsHigh-level thrombusProportional hazards analysisHigher T stagePostoperative disease recurrencePerioperative mortalityMedian followupDisease recurrenceTumor thrombusT stageTertiary hospitalEarly mortalityMulticenter study
2012
The use of isolated limb infusion in limb threatening extremity sarcomas
Vohra N, Turaga K, Gonzalez R, Conley A, Reed D, Bui M, Cheong D, Letson D, Zager J. The use of isolated limb infusion in limb threatening extremity sarcomas. International Journal Of Hyperthermia 2012, 29: 1-7. PMID: 23205633, PMCID: PMC4509503, DOI: 10.3109/02656736.2012.740548.Peer-Reviewed Original ResearchConceptsIsolated limb infusionExtremity soft tissue sarcomaSoft tissue sarcomasStable diseaseComplete responsePartial responseTissue sarcomasDownstaged to resectable diseaseIn-field response rateLong-term follow-upResponse rateLimb preservationGrade III toxicityLimb salvageSingle-institution experienceIntra-operative parametersRegional disease controlOverall response rateSignificant treatment challengeShort-term resultsMedian followupResectable diseaseExtremity sarcomasFollow-upPatient characteristicsA phase I evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advanced cancer of the esophagus and GE junction.
Astsaturov I, Meyer J, Cheng J, Olszanski A, Dushkin H, Berger A, Davey M, Cohen S, Burtness B, Scott W. A phase I evaluation of vandetanib plus paclitaxel, carboplatin, 5-fluorouracil, and XRT induction therapy followed by surgery for previously untreated locally advanced cancer of the esophagus and GE junction. Journal Of Clinical Oncology 2012, 30: 74-74. DOI: 10.1200/jco.2012.30.4_suppl.74.Peer-Reviewed Original ResearchSquamous carcinomaGrade 3 non-hematological toxicityOpen-label phase IOperable esophagealFox Chase Cancer CenterNon-hematological toxicitiesPathologic complete responsePhase I evaluationAST/ALTPromising clinical activityEsophageal squamous carcinomaPET/CTCarboplatin AUC5Male ptsAbdominal painCurative intentGI hemorrhageInduction chemoradiotherapyInduction therapyDistant recurrenceInduction chemoradiationMedian followupComplete responseAdvanced cancerDose escalation
2010
Patient Centered Outcomes in Prostate Cancer Treatment: Predictors of Satisfaction Up to 2 Years After Open Radical Retropubic Prostatectomy
Abraham NE, Makarov DV, Laze J, Stefanovics E, Desai R, Lepor H. Patient Centered Outcomes in Prostate Cancer Treatment: Predictors of Satisfaction Up to 2 Years After Open Radical Retropubic Prostatectomy. Journal Of Urology 2010, 184: 1977-1981. PMID: 20850836, DOI: 10.1016/j.juro.2010.06.099.Peer-Reviewed Original ResearchConceptsRadical retropubic prostatectomyOpen radical retropubic prostatectomyRetropubic prostatectomyProstate cancer treatmentBiochemical failureUrinary functionPredictors of satisfactionAmerican Urological Association symptom scoreCancer treatmentMultivariate analysis menProspective cohort studyMultivariate logistic regressionPatient-centered outcomeMeasures analysisHigh satisfaction rateShort-term satisfactionLong-term satisfactionAnalysis menClinical characteristicsCohort studyMedian followupPostoperative factorsPrimary outcomeAnastomotic strictureSymptom scores
1997
Ureteral Carcinoma in Situ at Radical Cystectomy: Does the Margin Matter?
Silver D, Stroumbakis N, Russo P, Fair W, Herr H. Ureteral Carcinoma in Situ at Radical Cystectomy: Does the Margin Matter? Journal Of Urology 1997, 158: 768-771. DOI: 10.1016/s0022-5347(01)64312-x.Peer-Reviewed Original ResearchConceptsUreteral carcinomaRadical cystectomyCarcinoma recurrencePositive cytologyMargin statusBladder cancerBacillus Calmette-Guerin treatmentRenal pelvis/ureterConsecutive radical cystectomiesUpper tract carcinomaUpper tract recurrenceCancer-specific survivalMetastatic bladder cancerPositive urinary cytologyFrozen section examinationLack of morbidityBladder tumor stageExpectant managementTract recurrenceMedian followupUreteral resectionSpecific survivalNegative marginsBladder tumorsTumor stageUreteral Carcinoma in Situ at Radical Cystectomy
Silver D, Stroumbakis N, Russo P, Fair W, Herr H. Ureteral Carcinoma in Situ at Radical Cystectomy. Journal Of Urology 1997, 158: 768-771.. PMID: 9258077, DOI: 10.1097/00005392-199709000-00020.Peer-Reviewed Original ResearchConceptsUreteral carcinomaRadical cystectomyCarcinoma recurrencePositive cytologyMargin statusBladder cancerBacillus Calmette-Guerin treatmentRenal pelvis/ureterConsecutive radical cystectomiesUpper tract carcinomaUpper tract recurrenceCancer-specific survivalMetastatic bladder cancerPositive urinary cytologyFrozen section examinationLack of morbidityBladder tumor stageUreteral marginsExpectant managementTract recurrenceMedian followupSpecific survivalUreteral resectionNegative marginsBladder tumors
1981
Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer.
Cohen M, Makuch R, Johnston-Early A, Ihde D, Bunn P, Fossieck B, Minna J. Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Journal Of The National Cancer Institute 1981, 65: 187-95. PMID: 6263468.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerLaboratory parametersLung cancerPerformance statusPrognostic factorsPrognostic indexSmall cell anaplastic lung cancerInfluential prognostic factorObjective prognostic indexPretreatment performance statusMajor prognostic factorSelf-limited eventAlpha-1 globulinCancer clinical trialsLaboratory resultsSignificant prognosticatorMedian followupAlbumin levelsMinimum followupPrognostic stratificationSurvival durationClinical trialsHigher hemoglobinTreatment response
1977
Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination.
Young R, Johnson R, Canellos G, Chabner B, Brereton H, Berard C, DeVita V. Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Journal Of The National Cancer Institute 1977, 61: 1153-9. PMID: 332349.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlood PlateletsClinical Trials as TopicCyclophosphamideDrug Therapy, CombinationFemaleHumansLeukocytesLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm StagingPrednisoneProcarbazineProspective StudiesRadiation DosageRadiation InjuriesRemission, SpontaneousTime FactorsVincristineConceptsHigher overall response rateCyclic combination chemotherapyOverall response rateCombination chemotherapyMedian followupResponse rateSimilar complete remission ratesRelapse-free survival rateComparison of chemotherapyMonths median followupComplete remission rateOverall median survivalDisease-free survivalTotal body irradiationNodular mixed lymphomaInduction regimenInduction therapyComplete remissionMedian survivalProspective trialRemission rateUntreated patientsMixed lymphomaMalignant lymphomaNodular lymphoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply